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Cancer immunotherapy relies on either restoring or activating the function of adaptive
immune cells, mainly CD8+ T lymphocytes. Despite impressive clinical success, cancer
immunotherapy remains ineffective in many patients due to the establishment of tumor
resistance, largely dependent on the nature of tumor microenvironment. There are
several cellular and molecular mechanisms at play, and the goal is to identify those
that are clinically significant. Among the hematopoietic-derived cells, monocytes are
endowed with high plasticity, responsible for their pro- and anti-tumoral function.
Indeed, monocytes are involved in several cancer-associated processes such as
immune-tolerance, metastatic spread, neoangiogenesis, and chemotherapy resistance;
on the other hand, by presenting cancer-associated antigens, they can also promote
and sustain anti-tumoral T cell response. Recently, by high throughput technologies, new
findings have revealed previously underappreciated, profound transcriptional, epigenetic,
andmetabolic differences amongmonocyte subsets, which complement and expand our
knowledge on the monocyte ontogeny, recruitment during steady state, and emergency
hematopoiesis, as seen in cancer. The subdivision into discrete monocytes subsets,
both in mice and humans, appears an oversimplification, whereas continuum subsets
development is best for depicting the real condition. In this review, we examine the
evidences sustaining the existence of a monocyte heterogeneity along with functional
activities, at the primary tumor and at the metastatic niche. In particular, we describe
how tumor-derived soluble factors and cell-cell contact reprogram monocyte function.
Finally, we point out the role of monocytes in preparing and shaping the metastatic
niche and describe relevant targetable molecules altering monocyte activities. We think
that exploiting monocyte complexity can help identifying key pathways important for the
treatment of cancer and several conditions where these cells are involved.
Keywords: monocytes heterogeneity, monocyte continuum, primary tumor, metastatic niche, targeting of
monocytes
INTRODUCTION
Monocyte diversity is well-recognized but the biologic and clinical significance of the different
monocyte subtypes is far from being completely elucidated. The main hallmark of monocytes
is their plastic nature, whereby they can exert multiple roles during the course of the immune
response including cytokine production, pathogen clearance, antigen presentation, wound healing,
and pro/anti-tumoral response (1–3). The original classification of monocytes into classical (in
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humans: CD14high, CD16−; in mice: Ly6Chigh), intermediate
(in humans: CD14high, CD16low), and non-classical (in humans
CD14low, CD16high; in mice: Ly6Clow) is currently being
replaced by evidences supporting the existence of a “monocyte
continuum” rather than stepwise differences between the
different subtypes (4). Indeed, in mice under steady state,
circulating classical monocyte subsets have been shown to
switch into non-classical monocytes over time (5–7). However,
it remains to be shown what relationship exists among the
human monocytic subsets, and whether and how pathological
conditions, like inflammation and cancer, impact this process.
Circulating monocytes have been viewed for many years, as
precursor cells that provide tissue macrophages and dendritic
cell (DCs) populations (8, 9); however, mounting evidence
suggests that monocytes have their own effector functions in
the blood and at peripheral sites throughout the body (10). The
emerging data that distinct monocyte subsets, carrying different
genetic, epigenetic, transcriptional, and metabolic arrangements,
are committed to become macrophages and DCs seems to
contradict the general accepted view of monocytes responding to
a particular environmental stimuli and then differentiating into
multifaceted macrophages and DCs. The intriguing evidence,
both in mice and humans (11–13), of trained-monocytes,
both present as mature and precursor cells, seems to strongly
support the former hypothesis and reinvigorate the idea that
monocytes have specific functions beyond being precursor cells.
In this review, by combining the most recent advances in
the field of monocytes’ genetic, epigenetic, transcriptomic, and
metabolomic, we outline and evaluate the changes occurring
in monocyte subsets that underlie the aforementioned plasticity
and heterogeneity. Secondly, we discuss new concepts in the
monocyte field, like trained immunity and reprogramming and
highlight the targetable pathways controlling monocyte fate
and function.
We think that combining the information of single-cell
transcriptome profiling, metabolomics array and epigenetic
studies will elucidate complex relationships between cell types,
thus solving limitations in the existing classification that relies on
a relatively small number of markers.
MONOCYTE PHENOTYPICAL AND
TRANSCRIPTIONAL PLASTICITY
Inflammatory and Patrolling Monocytes
Studies over the past two decades have delineated two major
subsets of monocytes in mice and humans. Inflammatory
monocytes (iMo), characterized by the high expression of the
chemokine receptor CCR2, are repeatedly released from the bone
marrow into the circulation. These cells, alternatively known
as classical monocytes, are Ly6Chi in mice and correspond
to the CD14hiCD16lo monocyte subset in humans. The fate
of these cells is strictly dependent on the state of the
body. Under steady state conditions, extravasated iMo and
their derived-cells enrich in nearly all tissues throughout the
body, where they form a small yet significant group of the
so called local tissue-resident macrophages (7). The gradual
accumulation of monocyte-derived macrophages in tissues is
generally associated with the slow but progressive replacement
of embryonic macrophages, in both quantitative and qualitative
fashion (14). Monocyte-derived macrophages present sustained
gene modifications as compared to their circulating counterparts,
as they shape to the tissue microenvironment. They acquire
transcriptional signatures resembling resident macrophages of
embryonic origin, even though a certain level of differences
remains at the epigenetic, transcriptional and functional levels
(15–17). Whether monocyte-derived macrophages that infiltrate
tissues under steady-state condition gain a self-renewal ability,
comparable to their embryonic counterparts, is still a matter of
debate and seems to strictly depend on the type of infiltrated
tissue. On the other hand, iMo can also conserve their
monocyte-like state inside the tissues without differentiating into
macrophages, thereby acting as a local monocyte reservoir (18)
(Table 1).
Besides the aforementioned pathway of maturation, iMo
can either remain in the blood, or transition into patrolling
monocytes (pMo) by the setting up of de novo enhancers
and activation of “frosted” enhancers (19, 20) (Table 1). The
mechanisms driving the conversion of iMo into pMo are just
beginning to be elucidated. It appears that Delta-like 1 (Dll1)
signal from endothelial cells by interacting with NOTCH2
only iMo favors their switch into pMo cells (21). These data
clearly indicate that iMo and pMo monocytes are biologically
intertwined, corroborating observation obtained at the epigenetic
level, which indicated that both monocyte subsets use the same
promoter repertoire and minimally differ in their chromatin
organization (19). Of course, this scenario raises several
questions: are the iMo infiltrating the tissues able to reprogram
into pMo? Is this switch tissue dependent? Can we interfere with
this reprogramming to control the transition? Is there any factor
maintaining iMo reservoir? Are pMo thus originated able to
re-enter the blood stream? Are monocyte-derived macrophages
transcriptionally similar to pMo? In mice, iMo can give rise
to pMo, even though this does not rule out the presence
of an alternative route for pMo development, independent
from the iMo subset (8). Indeed, genetic evidence for this
transition do exist. Two myeloid-determining transcription
factors, like interferon regulatory factor 8 (IRF8), and the
downstream Kruppel-like factor (KLF4), have been shown to
regulate iMo generation without affecting the pMo numbers.
Moreover, studies conducted on either global IRF8−/−mice,
or fetal liver transplant of KLF4−/−cells into irradiated wild
type mice, indicate a drastic reduced numbers of iMo in the
bonemarrow, while maintaining relatively normal pMo numbers
(22). These findings suggest a pathway for pMo development
untied from the iMo subset, probably originating directly from
the common monocyte progenitor (cMoP). The identification
of the transcription factors nerve growth factor IB (NR4A1)
has helped to withstand the hypothesis that pMo can arise
independently from iMo monocytes. On the other hand, recent
single-cell RNA sequencing of murine and human monocytes
indicate that circulating iMo and pMo represent, under
physiological conditions, a nearly homogenous populations (19).
Interestingly, data recently published (23) combining single
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TABLE 1 | Summary of monocyte subsets presented in this review, highlighting their markers and function in both humans (top part of the table) and mice (bottom part of
the table).
Monocyte subset Markers of identification Function
HUMAN
Inflammatory monocytes (iMo) CCR2+/CD14high/CD16low/neg Inflammatory response
Patrolling monocytes (pMo) CX3CR1+/CD16high/CD14low Tissue repair
Immunosuppressive monocytes
(M-MDSC)
CD11b+/CD14+/CD124+/PD-L1+/CCR2+/HLA-
DR−/ARG1/IDO1/cFLIP/IL-6/IL-10/TGFβ/STAT3/cEPBβ/NF-κB
Immune dysfunction, tumor angiogenesis and
vasculogenesis, promotion of metastasis,
promotion of tumor cell stemness
Trained monocytes CD14+/Dectin1+/CD36+/TLR4+/GM-
CSFR+/NOD/mTOR/ERK1/ERK2/NLPR3/HIF1α/aerobic
glycolysis/TNFα/IL-6/IL-1β/H3K18Ac/H3K4me/H3K27ac
Innate immune memory that balance the
equilibrium of balance of immune homeostasis,
priming, training, and tolerance
SatM-expressing monocytes Undefined Not yet identified in humans
Neutrophil-like monocytes Undefined Not yet identified in humans
MOUSE
Inflammatory monocytes (iMo) SSCint/CD11b+/F4/80+/CD64+/Ly6Chigh/CD43low/CD62L
+/CD115+/CCR2+/CX3CR1−/MHCIIlow/−/IRF8/KLF4
Inflammatory response
Patrolling monocytes (pMo) SSCint/CD11b+/F4/80+/CD64+/Ly6Clow/CD43
high/CD62L−/CD115+/CCR2−/CX3CR1+/MHCIIlow/TREML4
Tissue repair
Immunosuppressive monocytes
(M-MDSC)
CD11b+/Ly6C+/Ly6Glow/neg/CD124+/PD-
L1+/CCR2+/ARG1/NOS2/cFLIP/IL-6/IL-
10/TGFβ/STAT3/STAT1/STAT6/cEPBβ/NF-κB/Chop/S100A8/S100A9
Immune dysfunction, tumor angiogenesis and
vasculogenesis, promotion of metastasis,
promotion of tumor cell stemness
Trained monocytes Ly6Clow/Dectin1+/CD36+/TLR4+/GM-
CSFR+/NOD/mTOR/ERK1/ERK2/NLPR3/HIF1α/aerobic
glycolysis/lactate/mevalonate/TNFα/IL-6/IL-
1β/H3K18Ac/H3K4me/H3K27ac
Innate immune memory that balance the
equilibrium of balance of immune homeostasis,
priming, training, and tolerance
SatM-expressing monocytes Ly6Clow/Flt3−/FcεR1+/CEACAM1+/F4/80−/Mac1+/C5aR+/M-
CSFR+/MSR1+/cEPBβ/MPO- and NE-containing
granules
Fibrosis
Neutrophil-like monocytes Ly6C+/MPO- and NE-containing granules Response to microbial components (i.e., LPS)
and maintaining homeostasis at steady-state
profile and functional and phenotypic characterization, showed
that monocytes subsets (defined as classical, intermediate, and
non-classical) isolated from peripheral blood of both healthy
mice and humans, can be further divided into two additional
populations: one group expressing classical monocyte genes
and also cytotoxic genes and the other one with undefined
activity. Other studies conducted in human and mouse lung
cancer samples (24) have showed that several tumor-infiltrating
myeloid populations (TIM) and among those monocytes are
uniquely associated with the disease and with clinical progress,
highlighting the potential to use TIM as immunotherapeutic
targets. We think that the multiple cell subsets identified in
the aforementioned manuscripts, should be tested for their
functional relevance in tumor progression, in disease progression
and their abundance should be correlated with therapeutic
response. Of course, the correlation between human and
mouse TIM will help to achieve these goals with the ultimate
purpose of gaining more insight into monocytes and monocyte-
dependent therapies.
In contrast, patrolling monocytes (pMo) represent a more
differentiated subset and are marked by the higher surface
expression of CX3CR1. pMo express low levels of Ly6C in mice
and are CD14loCD16hi in humans; they routinely check the
vessels under physiological conditions through the engagement
of an LFA/ICAM-dependent crawling mechanism with resting
endothelial cells (25, 26). This patrolling behavior of pMo can
be observed throughout the interdigitated system of capillaries,
arterioles, and venules. Similarly, human CD14lo CD16hi pMo
show patrolling behavior when adoptively transferred into
immuno-compromised mice (27). The crawling features of pMo
allows them to efficiently sense particles, on the one hand,
and on the other hand to monitor of endothelial cell integrity.
However, these cells are not restricted to the vessels as pMo also
undergo diapedesis and can be identified within the parenchyma
of multiple tissues (7). pMo display a longer lifespan at the
steady state compared to iMo and they are, also for this reason,
found in the blood, at any given time, more abundant than
their counterpart (5, 28). Interestingly, pMo cells are strongly
susceptible of the physiological status of the organism and
therefore they might represent a potential diagnostic tool (29).
Nevertheless, how the fine balance between iMo and pMo
levels and differentiation capacity is maintained/regulated during
severe inflammation, autoimmune diseases, and cancer is just
began to be elucidated.
Under pathological conditions, such inflammation and
cancer, the rapid recruitment of myeloid cells to sites of injury
stimulates a constant development and mobilization of cells
from the bone marrow, causing a state of “emergency” that
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might generate monocytes from different ways or precursors.
These include monocytes that have circumvented the canonical
MDP-cMoP-monocyte developmental axes and resemble
neutrophil-like iMo derived from GMP precursors (30). An
additional example of a recently described monocyte subset
that appears under inflammatory conditions is the segregated
nucleus-containing atypical pMo (SatM) (31). SatM and
neutrophil-like monocytes represent a minor pool of monocyte
subsets under steady-state (19, 30, 31) (Table 1), yet become
conspicuous during inflammation (30, 31). At present, the lack
of reliable surface markers, associated with a deep epigenetic
and transcriptional profile unable to make a clear distinguish
between neutrophil-like iMo identified using GFI1/IRF8-
reporter mice (30) from classical iMo and SatM (identified as
Ly6ClowCeacam1hiF4/80−Mac1hi), from non-classical pMo
(31). The limited whole-cell proteomic data available so far
showed, for example, that SatM cells contain granules expressing
granulocyte-related protein, like myeloperoxidase (MPO) and
neutrophil elastase (NE) (31) (Figure 1). These cells are related to
fibrosic responses; in fact, adoptive transfer of SatM monocytes
into bleomycin-treated mice exacerbates fibrosis. Furthermore,
it was shown that chimeric mice, lacking the CCAAT/enhancer-
binding protein beta (Cebpb) in the hematopoietic progenitors
were resistant to fibrosis when exposed to bleomycin but they
had unaltered inflammatory response, further supporting the
role of SatM in sustaining the mechanism of fibrosis (31).
Nevertheless, more studies will be required to uncover the origin
of these subsets and their involvement in different pathologies.
To add more complexity, a recent work by Hanna et al. (32),
showed that a subset of circulating pMo, but not iMo, accumulate
at the site of tumor where they display an anti-tumoral role, by
directly engulfing cancer cells and by releasing factors which
in turn activate cytotoxic natural killer cells (NK). Are these
extravasating pMo similar to their blood counterpart? How
the findings from Hanna et al. (32) correlate with observations
that extravasating pMo can differentiate into macrophages
during cancer? Are pMo “corrupted” by tumor cells once they
have extravasated within tissues and switched to pro-tumoral
cells? Are iMo and pMo competing for the access to the tumor
site? Are iMo suppressing the anti-tumor function of pMo?
Indeed, this mechanism is also consistent with the data from
the pMo adoptive transfer experiments since pMo appear to act
early during seeding but not after establishment of metastatic
foci despite their continued accumulation. Therefore, under
pathological conditions it still remains possible that pMo derive
from either blood iMo, via the formation of an intermediate
Ly6Cint monocyte, or from bone marrow Ly6C+ monocytes,
from an independent bone marrow monocyte progenitor, or
from a combination of all these pathways (Figure 1). In order
to solve all these issues a detailed understanding of the factors
and pathways regulating the development and survival of both
iMo and pMo populations in specific inflammatory settings
is necessary.
As mentioned before, adoptive transfer and fate-mapping
studies support the hypothesis that monocytes develop along a
differentiation continuum in which inflammatory monocytes
give rise to the patrolling subset in the circulation (3, 5).
Development of monocytes from bone marrow progenitors
combines the regulated expression of numerous transcription
factors, with the contribution of growth factors and cytokines
(33). Monocytes and neutrophils are both derived from
hematopoietic stem cells (HSCs) via common myeloid
progenitors (CMPs), which can originate from granulocyte-
monocyte progenitor (GMP) and monocytes/macrophages, DC
precursors (MDPs) (34, 35) (Figure 1). The commitment toward
monocytes is characterized by three major lineage-determining
factors (LDTF): PU.1, CCAAT/enhancer-binding protein beta
(Cebpb) and Cebpa. PU.1 is a master regulator of myeloid and
lymphoid cell development (36). The genetic ablation in mice of
PU.1 promotes a lethal embryonic phenotype and the transfer
of PU.1 mutated stem cells favors an altered myelopoiesis
characterized by a robust contraction in both monocytes and
DCs (37, 38). By binding closed chromatin through its C-
terminal DNA-binding domain (39), PU.1 acts as a coordinator
for the activation of selected genomic regions in collaboration
with monocyte-associated transcriptional factors such as the
IRF8 and KLF4 (40). Moreover, PU.1 synergistically cooperates
with C/EBP-δ to activate the promoters of interleukin-6 (IL-
6) and CCL5 (41) and transactivates the human macrophage
colony-stimulating factor receptor (M-CSFR) promoter via the c-
Jun pathway (42). Proteins of the C/EBP family radically impact
the myeloid cells development. Since in Cebpa-deficient mice the
transition from CMPs to GMPs is completely abrogated, these
mice lack the granulocytic compartment (43, 44) indicating that
C/EBPα is the master regulator of steady-state granulopoiesis.
Additionally, during myelopoiesis, C/EBPα controls and
activates the myeloid-associated gene expression program by
binding to either promoters or enhancers of myeloid-related
genes, such as colony stimulating factor 3 receptor (CSF3R),
growth factor independent-1 (GFI-1), interleukin 6 receptor (IL-
6R), or C/EBPε, both in mice and in human stem cells (45).
C/EBPα inhibits specific transcriptional factors attenuating the
expression of non-myeloid lineage genes (46, 47). Moreover,
genetically enforced inducible C/EBPα expression in GMPs
by tamoxifen administration favors monocyte development
demonstrating the critical role of this transcriptional factor
during monopoiesis (48). By contrast, C/EBPβ is not necessary
for steady-state granulopoiesis. However, C/EBPβ was recently
identified as the key factor during the epigenetic default
differentiation of iMo monocytes into pMo cells under steady
state condition, highlighting the multifaceted role of this
transcriptional factor during monocyte development (19). In
this regard, a key contribution of C/EBPβ to mylopoiesis is
highlighted by data showing that mice knockout for Cebpb have
a dramatic reduction in circulating monocytes (19). C/EBPβ
is also the master regulator of emergency myelopoiesis; in
fact, inflammatory signals (i.e., cytokine stimulation) strongly
induce the downregulation of all members of C/EBP family
except for C/EBPβ (43). Under pathological condition, like
fibrosis, a C/EBPβ-associated gene program in FcεR1+ GMPs
progenitors promote the development of alternative monocytes,
like SatM, previously described. As we will discuss below,
C/EBPβ-driven programs are also activated in cancer-educated
myeloid cells.
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FIGURE 1 | Layout depicting the monocyte lineage precursors (on top), the monocyte subsets in the peripheral blood (center), and monocyte fate in cancer tissues.
Indicated are relevant surface markers, transcription factors, secreted cytokines, intracellular mediators, and relevant metabolic pathways. Continuous lines indicate
events occurring during normal myelopoiesis while shaded lines indicate events in emergency myelopiesis (e.g., cancer and inflammation). Briefly, under steady state
cMop precursors originate both inflammatory (1) and patrolling (2) monocytes, both in humans and mice. However, it has been reported that during emergency
myelopoiesis cMop precursors can also differentiate into M-MDSC (3) and into not yet defined immature cells (4). Particularly, during infection, inflammatory
monocytes acquire a trained phenotype (5) and also switch into Ly6Cint cells (6) only identified in mice and with not fully defined function, transcriptional regulators,
(Continued)
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FIGURE 1 | and markers. During fibrosis a novel subset of monocytes, so called SatM (8), have been characterized, in mice, defined as Ly6C+ and expressing
proteins typical of the neutrophil granules (MPO and NE). These cells, together with neutrophil-like monocytes (7), found in peripheral blood of mice during microbial
infection and in the bone morrow in steady-state condition, originate from GMP/FcεRI+ precursors cells in the bone marrow. In pathological conditions, like cancer,
inflammatory monocytes infiltrating the tissue give rise to TAM (9) which in turn represent a fultifaced population of macrophages. Additionally, inflammatory monocytes
can also differentiate into classical DC (10) expressing the costimulatory molecules CD80 and CD86 and TipDC (11) expressing high level of NOS2 and TNFα.
Myeloid-Derived Suppressor Cells
In cancer, tumor-derived soluble factors, such as growth factors,
cytokines, chemokines, and tumor-derived exosomes, not only
support an increased recruitment of monocytes from bone
marrow to tumor-microenvironment bypassing the canonical
monocyte development but, also, favor the acquisition of
immunosuppressive features in myeloid cells. To highlight
these acquired functional properties, myeloid cells comprising
monocytes, neutrophils, and immature cells were named
myeloid-derived suppressor cells (MDSCs) (49, 50). Although
this terminology generated some controversies, it represents a
useful ground for scientific researches on altered hematopoiesis.
It relies on the concept that myelopoiesis in pathology might
give rise to cellular subsets that can share some markers
with the cells present under steady state but are functionally
and molecularly distinct, sharing the property of negatively
regulating effectors of adaptive and innate immunity. The
monocytic-MDSC (M-MDSC) subset is broadly defined in
mice as Ly6C+CD11b+ cells and in human as CD14+HLA-
DR− or CD14+CD124+ cells and is endowed with a stronger
ability to arrest T cell response, when compared to the
granulocytic-MDSC (G-MDSC) counterpart (51, 52), in part
dependent on the activation of two enzymes, arginase 1 (ARG1)
and inducible nitric oxide synthases (NOS2/iNOS), which
are directly regulated by C/EBPβ expression (53) (Figure 1;
Table 1). We demonstrated that, in tumor-bearing mice, both
the expansion and the immunosuppressive function of MDSCs
are abrogated in the absence of C/EBPβ, resulting in restricted
tumor spread (53). These data confirm the central role of
C/EBPβ in tumor-associated inflammation, underscoring it as
promising therapeutic target to develop new approach to limit
cancer progression. Both human and mouse M-MDSCs secrete
immunoregulatory cytokines, like IL-10, TGFβ, and IL-6 and
present and array of molecules, such as ARG1, FADD-like IL-
1β-converting enzyme-inhibitory protein (c-FLIP), indoleamine
2,3-dioxygenase 1 (IDO1), and nitric oxide synthase 2 (NOS2),
which can contribute to the suppressive activity of these
cells. Mechanistically, IL-6, for example, activates PI3Kγ,
which stimulates mTOR, S6Kα, and C/EBPβ-mediated anti-
inflammatory gene expression and inhibits NFkB-mediated pro-
inflammatory gene expression, thereby promoting the immune
suppressive function of these cells mediated by, but not limited
to, IL-10, TGFβ, and ARG1 (54, 55). In particular, Arg1 gene in
MDSCs is strictly controlled by several inducible transcriptional
factors able to recognize sequences characterized by high content
in GC that impacts the nucleosomal stability (56), such as
signal transducer and activator of transcription 3 (STAT3),
IRF8, as well as CHOP, PU.1, KLF4, and activator-protein 1
(AP-1) (57). Moreover, STAT3 promotes both expansion and
survival of M-MDSCs through Bcl-XL, c-Myc, and Cyclin D1
expression (58) as well as the induction of several immune
regulatory mediators like bFGF, HGF, VEGF, IL-1β, MMP9,
CCL2, and CXCL2 (50). Interestingly, phosphorylated STAT3
binds to multiple sites in the Arg1 promoter, suggesting that
STAT3 inhibitors, like Stattic, could reduce ARG1 dependent
immunosuppression by dampening the expression of Arg1
mRNA (59). Within the tumor environment, ARG1 can
cooperate with NOS2 to produce high levels of superoxide
anion (O−2 ) that can react with either nitric oxide (NO)
or H2O generating reactive–nitrogen species (RNS), such as
peroxinitrites (ONOO−), which damage both the function and
migration of T cells to tumor site (60), and reactive-oxygen
species (ROS), such as H2O2 which decreases T cellular CD3ζ
expression limiting the activation of T cells, respectively (61).
However, ARG1 has a hierarchically dominant negative role
compared to NOS2 in developing an immunosuppressive tumor
microenvironment by limiting the activity of monocyte-derived
NOS2-expressing and TNF-producing dendritic cells (defined as
Tip-DCs) that can sustain and favor the anti-tumor effect of
transferred T lymphocytes (62). An alternative way to reprogram
MDSC differentiation and function is through the expression
of p53. It was recently demonstrated that M-MDSC can be
driven to differentiate into potent antigen-presenting, defined
as Ly6C+CD103+ DCs by inflammation-induced activation
of p53. In fact, mice with a targeted deletion of p53 in
myeloid cells specifically loose the Ly6C+CD103+ population
and became unresponsive to different forms of immunotherapy
and immunogenic chemotherapy (63).
Recently, we demonstrated the ability of c-FLIP, which
controls the extrinsic apoptotic pathway and caspase 8 activation
(64), to re-program monocytes into MDSC-like cells (65). In
fact, FLIP-expressing monocytes displayed impressive regulatory
features both in vitro, constraining the activated T cell
proliferation, and in vivo, controlling the development of
graft vs. host disease in a xenogeneic mouse model. Indeed,
enforced expression of c-FLIP inmonocytes up-regulatesMDSC-
associated immunosuppressive genes, such as CD273, CD124,
IL-6, IL-10, CFS3, PTGS2, and IDO1, as a result of a “steered”
NF-kB activation induced by the nuclear co-localization of c-
FLIP with NF-kB p50 (65). During the course of a disease, like
cancer, MDSCs infiltrate the tumor, differentiating into tumor-
associated macrophages (TAMs) which can sustain primary
tumor growth and contribute to the pre-metastatic niche
formation (Figure 1).
Trained Immunity and Metabolic
Landscape of Monocyte Subsets
Recent studies have shown that during infection with some
pathogens iMo can undergo extensive epigenetic, transcriptional,
and metabolic reprogramming, with the functional consequence
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of an enhanced immune reactivity upon a second encounter,
in other words they acquire an immunological memory. The
existence of this innate immune memory was initially suggested
by studies in mice deficient for functional T and B cells and
exposed to mild C. albicans infection, which show protection
against C. albicans reinfection by increased responsiveness of
monocytes (66). Even though the requirements for monocyte
training has been primarily investigated either in vitro or
under in vivo steady state, trained monocytes seem to originate
from iMo during emergency hematopoiesis by a profound
epigenetic and metabolic rewiring (Table 1). Exposure of iMo
to either C. albicans or β-glucan in vitro, induce profound
genome-wide changes in epigenetic marks, including, but not
restricted, histone H3 lysine 4 monomethylation (H3K4me1),
trimethylation (H3K4me3), and H3 lysine 27 acetylation
(H3K27ac) (67) as a consequence of Dectin-1/AKT/mTOR/HIF-
1α signaling pathway activation and secretion of IL-6, IL-1β,
and TNFα. Other studies instead, identified Bacille Calmette-
Guérin (BCG) and peptidoglycan as potent inducers of
the aforementioned trained-related epigenetic modifications,
though a different mechanism dependent on nucleotide-binding
oligomerization domain-containing protein 2 (NOD2) pathway
and activation of NF-kB (68). Concomitantly to these epigenetic
changes, a metabolic switch also occurs. Trained monocytes are
mainly glycolytic (aerobic glycolysis) with impairment of the
oxidative phosphorylation, production of lactate and disruption
of the Krebs cycle at the level of both citrate, which is withdrawn
for fatty acid biosynthesis, and succinate, which activates HIF-
1α and consequently up regulates the expression of several pro-
inflammatory cytokines, mainly IL-1β and TNF-α (69).
Beside microbial particles, products of the lipid metabolism
were found to be activators of the trained immunity. Oxidized-
low density lipoprotein (oxLDL), a damage-associated molecular
pattern (DAMP), interacts with CD36 on myeloid cells leading
to the activation of NLRP3 inflammasome and consequent
production of IL-1β (70–72).
Although the role of epigenetic programing as a mechanism
required to insure innate immune memory is becoming more
clear, one crucial aspect still remains unanswered: what is the
cellular process that induces and maintains such epigenetic
changes? Initial evidences seem to suggest that metabolites might
play a role since they can act as cofactors for the enzymes
(mainly methylases, methyltransferases, histone deacetylases,
and histone acetylases) involved in epigenetic modulation of
gene transcription (67, 73, 74). Of course, more studies are
required to fill the gap and also to deeply examine the role
that different chromatin modifications have on the stability of
the chromatin. It is expected that stable histone modifications
(e.g., histone methylation) would be more suitable to maintain
a functional modification than those with short half-life (e.g.,
histone acetylation). Thus, the long-lasting persistence of
some histone modifications could reflect both the stability of
such modifications or the persistent activation status of the
signaling pathways and transcription factors upstream (75, 76).
Understanding these regulations is a sine qua non for designing
therapeutic intervention aimed at modulating trained immunity,
to dampen it when in excess (e.g., organ rejection, autoimmunity,
allergy, atherosclerosis) or enhance it when defective (e.g.,
cancer, infection).
A growing body of evidence suggests that the development
of immune cells and their different effector functions are
the results of a dynamic changes occurring at the metabolic
level (77, 78). In mouse models of cancer, myeloid cells
are metabolically influenced by tumor-derived factors to
become MDSCs, helping to protect tumor from the effects
of chemotherapy (79). Specifically, mouse MDSCs undergo a
major metabolic reprogramming by switching off glycolysis and
enhancing fatty acid β oxidation (FAO) pathway. This metabolic
reprogramming is generally characterized by an up-regulation
of lipid uptake receptors CD36 and Mrs1, an increase in FAO
enzymes, mainly carnitine palmitoyltransferase 1 (CPT1) and
3-hydroxyacyl-Coa dehydrogenase (HADHA), and an increase
in oxygen consumption. These events are associated with the
activation of immunosuppressive pathways, namely upregulation
of ARG1 and NOS2 synthesis and production of ONOO−,
contributing to dampen T cell proliferation and IFNγ secretion
(80–82). Blockade of FAO, both in vitro and in vivo in different
tumor models, decreased the incorporation of fatty acid and
ATP production, holding up the development of suppressive
MDSCs (82) and leading to increased efficacy of chemotherapy
and adoptive T cell therapy. Interestingly, fatty acid oxidation
also plays an important role in regulating the inflammatory
properties of iMo. Increased intracellular level of unsaturated
fatty acid (arachidonic acid) was shown to stimulate the secretion
of pro-inflammatory IL-1α by uncoupling the mitochondrial
respiration (83, 84) thus exacerbating the pathogenesis of
atherosclerosis (85). The relevance of changes in the lipid
metabolism occurring during myeloid cells differentiation, was
also recently demonstrated by Mitroulis et al., in an vivo model
of trained immunity (13). Treatment with β-glucan determines
an increase in gene expression of several enzymes involved in
cholesterol biosynthesis and decrease in expression of Abca1,
a transporter regulating cholesterol eﬄux (86). Consistently,
β-glucan administration in mice not only upregulates CD131,
a subunit of the receptor for IL-3, IL-5, and GM-CSF,
expression in myeloid precursors, but also activates downstream
signaling, as demonstrated by STAT5 phosphorylation. The
capacity of β-glucan to enhance the biosynthesis of cholesteryl
esters and significantly decrease glycerophospholipid-containing
arachidonic fatty acid chains highlight the capacity of cells to alter
their lipidome and, thus, the physicochemical features of their
membranes. This adaptive response has direct consequences in
the composition of cellular membranes (87) and consequently in
cell signaling (88). In this regard, alterations in the quantitative
and qualitative cholesterol composition of the membrane can
impact the localization of CD131, its signaling (86, 89) and
consequently the differentiation of specific myeloid subsets.
Amino acids, besides being the building block of several
molecules, serve as essential precursors of different metabolites.
Different studies have shown that glutamine metabolism into
glutamate, α-ketoglutarate and succinate semialdehyde can fuel
the synthesis of fumarate and succinate for the tricarboxylic
acid cycle (TCA) (90). Inhibition of glutaminolysis, in mice,
down regulates the production of pro-inflammatory cytokines in
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monocytes exposed to C. albicans, dampening the development
of efficient trained monocytes triggered by β-glucan. In line
with these observations, the biochemical catheterization of β-
glucan trainedmonocytes has revealed that upon induction of the
signaling cascade Dectin-1-Akt-mTOR-HIF-1α, a metabolic shift
occurs leading to an increase aerobic glycolysis, glucose usage,
lactate production, and TNF-α secretion (67).
Thus, it appears that modulation of metabolic landscape
represents a fundamental step to unravel the functional
consequences of different monocytes subsets helping to identify
new strategies of intervention for the treatment of several patho-
physiological conditions. It remains instead undefined whether
cancer-derived factors can also generate trained monocytes and
if these cells contribute to dampen the anti-tumor response or
favor metastatic spread.
MONOCYTE FUNCTIONS
Monocytes at the Primary Tumor
Tumor derived factors (TDFs) are key mediators in the crosstalk
between monocytes and tumor cells. They are involved in
monocyte recruitment from the hematopoietic organs in adult
life, i.e., bone marrow and in part the spleen, survival, and
differentiation within the tumor site. Tumor-released monocyte
chemoattractant protein-1 (MCP-1, also known as CCL2) was
identified as the major TDF involved in iMo recruitment,
through the CCL2-CCR2 axis, into several mouse and human
tumors (91). Indeed, inhibition of CCL2-CCR2 signaling in
a mouse model of breast cancer significantly impair iMo
infiltration and reduce tumor growth and metastases (92).
Several studies have described the presence of other chemokines
within the tumor microenvironment (TME), including CCL3,
CCL4, CCL5, CXCL12, and growth factors such as colony
stimulating factor-1 (CSF1), which may also contribute to
monocyte recruitment to tumors (93). Indeed, in both mouse
(94) and human (91) tumors, cells secrete high level of CSF1
that is involved in recruitment, survival, and differentiation
of monocytes. The inhibition of CSF1 signaling in an
experimental model of lung carcinoma significantly reduced
the number of mature TAMs due to impaired recruitment,
proliferation and maturation of iMo cells (95). Moreover, CSF1R
signaling blockade can also reprogram immunosuppressive
TAMs prompting the differentiation of iMo in anti-tumoral
M1-like TAMs (96). However, abrogation of CSF1R signaling,
by either small molecules (97) or monoclonal antibodies (98),
even though appealing, have so far demonstrated a limited anti-
tumor effects. Only a recent work done by Kumar et al. (99)
highlighted that the CSF1-dependent cross-talk between tumor
cells and cancer-associated fibroblasts (CAF) might explain the
inefficacy of such a treatment. Thus, combinatorial therapy
targeting both CSF1R and CXCR2 seems to have more chances
to generate an effective anti-tumor T cell response. Thus,
the therapeutic focus has shifted to combinations of CSF1R
inhibitors with other agents. Indeed, treatment with CSF1
inhibitor in combination with either paclitaxel or radiotherapy,
is showing to improve the survival of mouse model of breast or
prostate cancer, respectively (79, 100) and improve the efficacy
of ACT when combined with anti-PD-1 and anti-CTLA4 in
a pancreatic mouse model (101). It is becoming clear that
cytotoxic therapies, for example, induce mammary epithelial
cells to produce monocyte/macrophage recruitment factors,
including CSF1 and interleukin-34 (IL-34), which together
enhance CSF1R-dependent monocytes/macrophage infiltration,
making its inhibition more effective.
One of the strongest stimuli inducing the secretion of TDFs
is hypoxia. Indeed, during tumor growth the level of available
O2 is significantly reduced, especially in the inner part of the
neoplastic mass. This hypoxic microenvironment triggers HIF-
1α stabilization in tumor cells and the consequent release of pro-
angiogenic factors, such as growth factors (VEGF, PDGF, PIGF,
ANG-2), chemokines (CXCL8, CXCL12), cytokines (TNFα,
IL1β, TGFβ), and metalloproteases (MMPs), which results in
the sprouting of new vessels supporting cancer cells growth
(102, 103). In addition, hypoxia is a powerful monocyte and
macrophage attractant. Through the release of VEGFB and
PIGF, tumor cells can enhance haematopoiesis and monocyte
recruitment (104). In addition, angiopoietin-2 (ANG-2) is able
to recruit circulating Tie2-expressing monocytes (TEMs) that
inhibit apoptosis in both tumor and endothelial cells, by
mechanisms depending on TNFα release (105), and exhibits an
essential pro-angiogenetic role with a not completely clarified
mechanism. Interestingly, it was recently discovered that a small
subgroup of recruited iMo can be educated by VEGF, and
exert their proangiogenic function, supporting the formation
of capillaries and larger vessels, as short-lived monocytes
without becoming macrophages (106). Secreted VEGF promotes
the acquisition of immunosuppressive features in monocytes
generating M-MDSCs by upregulating both ARG1 and iNOS
through hypoxia response elements and NF-kB (107). In
addition, MDSCs can fuel this circuit by releasing MMP-9, which
induces VEGF release from ECM (108). Therefore, targeting
VEGF/VEGFR has received attention as a strategy to interfere
with monocyte-driven angiogenesis. Moreover, blocking this axis
will affect monocytes recruitment to the tumor site (109), and
favor the conversion from predominant suppressive to anti-
tumoral monocytes (110). An additional way to interfere with
MDSC differentiation is by interfering with p53 expression, as
mentioned before (63).
In the last few years, extracellular vesicles (EVs) emerged
among the TDFs as additional determinants in the formation
of TME, both at primary and metastatic sites (111). EVs are
a heterogeneous group of membrane vesicles mainly composed
of exosomes and microvesicles. Interestingly, EVs released by
tumor cells (tEVs) and tumor-derived exosomes (TEX) interact
with immune cells inducing their switch toward a pro-tumoral
phenotype. Particularly, exosomes target monocytes altering
their normal function by several mechanisms. In melanoma and
colon cancer, TEX block peripheral iMo differentiation into DCs,
and favor the acquisition of a peculiar phenotype reminiscent of
M-MDSCs and characterized by decreased expression of HLA-
DR and costimulatory molecules (112). A similar modulation
of monocytes has been described in many other malignancies,
including pancreatic cancer, bladder carcinoma, glioblastoma,
and multiple myeloma (113–115) and it is often associated
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with increased cytokine secretion, i.e., CCL2, CCL4, and IL-
6, as well as programmed death-ligand 1 (PD-L1) expression
(116). Moreover, glioblastoma-derived EVs may skew the
differentiation of peripheral blood monocytes to alternatively
activated M2 macrophages inducing the expression of elevated
levels of VEGF, IL6, Cox2, ARG1, and PD-L1 through STAT3
activation (117). Interestingly, in gastric cancer, TEX effectively
educated monocytes to differentiate into a peculiar type of
M2 TAM expressing PD-1, which induce T cell dysfunction
through IL-10 secretion by interacting directly with PD-L1+
cells and thereby promote tumor progression (118). TEX have
been described to contain miRNA which can be transferred to
target cells and modulate cellular function (119). These data
strongly highlight the role of TEX as additional mediators of
monocyte dysfunction in TME. In the last few years, significant
advances in understanding the mechanisms associated with
exosome biogenesis/release have been obtained identifying some
possible targets to interfere with this cell-cell communication.
Recent studies in mouse models demonstrated that RAB27A or
RAB35 inhibition significantly impair TEX secretion in HeLa
cervical carcinoma and Oli-Neu oligodendroglial precursor cell
lines (120), respectively. Moreover, RAB27A deficient tumor cell
lines displayed reduced growth due to impaired recruitment of
bone-marrow derived, pro-tumoral immune cells (121).
In addition to be modulated by soluble factors released by the
tumor cells, monocytes can shape their effector function also in a
contact-dependent manner. For instance, breast cancer stem cells
express CD90 and Ephrin A4 receptor (EphA4R) that interact
with CD11b and EphA4 present on tumor-associated monocytes
and macrophages, respectively, leading to the secretion of
inflammatory cytokine (IL-6, IL-8, GM-CSF), which in turn
sustain tumor stem cell fate (122).
Among factors that could shape monocyte plasticity, TGFβ,
a key multifunctional cytokine, involved in both cancer and
inflammation, appears to play a key role. Besides being targeted
in a number of human diseases (123), TGFβ has a very
well-recognized ability to regulate T cell responses (124),
supporting Th9 (125, 126) and Th17 (127) differentiation,
and promoting regulatory T cell function (128–130). However,
how TGFβ regulates innate immune responses just began
to be appreciated. Many TME-associated cells, and among
those monocytes and macrophages, express high amount
of latent LTGFβ. The recent work by Kelly et al. (131),
demonstrates that iMo, beside tumor cells, express high
levels of αvβ8 integrin responsible for the activation TGFβ
from LTGFβ form (131, 132). Additionally, monocyte-derived
macrophages, integrin expression and TGFβ signaling are
generally maintained in anti-inflammatory macrophages but
down-modulated in pro-inflammatory macrophages. To sustain
the immunosuppressive microenvironment, tumor cells exploit
this regulatory mechanism upregulating the expression of
integrin αvβ8 and activating TGFβ from LTGFβ-expressing
monocytes and macrophages (133).
Monocytes at the Metastatic Niche
Cancer metastasis is a multi-step process of the neoplastic
progression termed “invasion-metastasis cascade” (134, 135).
Monocytes are, among other myeloid cells (e.g., neutrophils),
corrupted to foster tumor progression and metastasis.
Accumulating evidence indicates that monocytes (primarily
iMo) are essential pre-metastatic promoters being rapidly
recruited from the bone marrow to the pre-metastatic niche,
mainly by CCL2/CCR2 axis (136, 137), where they promote
tumor colonization by secreting angiogenic factors, like VEGFA
(92, 138). Indeed, in the MMTV-PyMT mouse model of
spontaneous breast cancer, CCL2, released by either tumor
cells or stromal cells at the metastatic lung niche, induces
the recruitment of CCR2-expressing iMo, which in turn
favor the extravasation of tumor cells, through the release of
VEGFA (92). Consequently, the inhibition of CCL2-CCR2
signaling axis abrogated the recruitment of monocytes thus
reducing metastasis formation. Similarly, in a mouse model
of metastatic melanoma (B16F10 model), accumulation of
CXCR3+monocytes/macrophages in the lung was a prerequisite
to mediate melanoma engraftment and metastatic disease (139).
However, how this process takes place remains undefined. In
a different set of experiments employing B16F10 melanoma
model, it was shown that M-MDSCs were recruited to the
pre-metastatic niche, mainly by CCL12 expression. By releasing
IL-1β, these cells promoted the expression of E-selectin on
endothelial cells thus promoting the adhesion of tumor cells to
the vascular endothelium (140).
At the metastatic targeted-organs, monocytes can offer
survival stimuli for cancer cells. Metastatic cells in the lung,
from either mouse or human breast cancer, overexpress vascular
cell adhesion molecule-1 (VCAM-1) and shRNA-mediated
depletion of VCAM-1 inhibited metastasis formation. Moreover,
monocytic cells expressing α4-integrin can bind VCAM-1
present on the surface of tumor cells. Thus, upon α4-integrin
engagement on monocytes, VCAM-1 delivers anti-apoptotic
signals into breast cancer cells through the PI3K/Akt pathway
favoring tumor cell survival (141).
EVs can cross the basal lamina of alveolar capillaries in the
lung. In the lungs, alveolar and interstitial macrophages upon
taking up these EVs start to secret CCL2 favoring the recruitment
of iMo, which in turn differentiate into macrophages, mostly
M2-like cells, promoting tumor growth by the secretion of IL-
6 and deposition of fibrin (142). Similarly, in colorectal cancer
(CRC) patients the high expression of serum exosomal-derived
miR-203 was associated with increased probability to develop
distant metastases. It was shown that TEX-derived miR-203
uptaken by monocytes promoted their differentiation into M2-
like macrophages, in vitro. Furthermore, mice injected with CRC
cells transfected with miR-203 developed significantly more liver
metastases than the control group (143).
We have previously underlined the plasticity of monocytes
and how iMo and pMo play different roles in cancer progression
and surveillance. In line with these observations, it has been
demonstrated that TEX from poorly-metastatic melanoma
cells are taken up by bone-marrow monocytes, promoting
their differentiation into pMo, which in turn migrate at the
metastatic niche clearing tumor cells by direct engulfment or
by activating cytotoxic NK cells (144). Interestingly, TEX from
poorly-metastatic tumors caused macrophage alteration toward
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M1-like cells expressing TRAIL, which competed with NK cells
for tumor killing. These findings suggest that prior to the
acquisition of the metastatic capacity, tumors continuously alert
host immune system by producing vesicles that affect innate
immune responses and support the concept of developing new
cancer immunotherapeutic approach based on TEX to deliver
specifically immune triggers.
FUTURE PROSPECTIVE: TARGETING OF
MONOCYTES AS THE NEW FRONTIER
FOR CANCER IMMUNOTHERAPY
Myeloid cells are extremely plastic and can develop specialized
functions in response to micro-environmental pathologic
conditions such as infections, autoimmunity or cancer (145).
Myeloid cell polarization into either tumor-suppressive or
tumor-promoting phenotypes is fundamental for shaping TME.
Once at the tumor site, these myeloid cells generally acquire
a pro-tumor phenotype (146). Thus, one of the major goals
of contemporary tumor immunotherapy is targeting tumor-
associated myeloid cells by depletion, recruitment inhibition or
reprogramming their polarization/activation status.
As mentioned above, inhibition of the CCL2-CCR2 axis,
used to prevent the egression of monocytes from bone
marrow, improved the efficacy of chemo-, radio- and immune-
therapy in several preclinical models. Nevertheless, the use
of either CCL2 or CCR2 inhibitors, in clinical trials, gave
disappointing results, indicating the need of supplementary
studies considering the presence of potential TME-dependent
compensatory mechanisms acting on tumor-resident myeloid
cells (146, 147). Moreover, although the continuous blockade
of macrophages constrains tumor progression, cessation of the
CCL2 blocking therapy stimulates them to a rapid rebound,
leading to accelerated metastatic disease via a mechanism
dependent on VEGF-A and IL-6 production monocyte-derived
by macrophages (102).
Targeting Trained Immunity
Trained immunity inducing factors were tested for their
anti-tumor activity, both in vitro and in vivo, and some
of them reached the clinical application. A β-glucan PAMP,
Imprime PGG (Imprime), is currently in clinical development
in combination with immune checkpoint inhibitors, tumor-
targeting antibodies, and anti-angiogenic antibodies. The results
from a randomized phase 2 clinical trial of Imprime in
combination with bevacizumab and carboplatin/paclitaxel vs.
bevacizumab and chemotherapy alone in the 1st-line treatment
of stage IV non-small cell lung cancer showed promising
efficacy in terms of both objective tumor response and survival
(ClinicalTrials.gov NCT 00874107, EudraCT 2008-006780-37).
Earlier results have shown that both the M2 macrophages and
DCs derived from Imprime-trained monocytes have higher
expression of PD-L1 and CD86, rendering these cells suitable for
treatment with anti-PD-1 antibody. Ex vivo treatment of T cells
with Nivolumab, an anti-PD-1 antibody, enhanced proliferation
in response to αCD3/αCD28 stimulation and co-culture with
Imprime-trained monocytes-derived M2 macrophages or DCs
further improved T cell expansion and increased production of
several cytokines, including IFNγ, IL-2, TNF-α, and GM-CSF.
Results were further validated in syngeneic mouse model, like
the CT26 colon carcinoma. Bacillus Calmette-Guerin (BCG),
another trained immunity inducer, is currently the only agent
approved by the US Food and Drug Administration for first
line treatment of carcinoma in situ of the bladder. BCG therapy
reduces the risk of recurrence and maintenance therapy with
BCG decreases the risk of progression in patients with high-
grade, non–muscle invasive bladder cancer (148, 149). It has been
speculated that the mechanism of action involves the autophagy.
In fact, pharmacologic or genetic inhibition of autophagy blocks
the epigenetic reprogramming of monocytes at the level of H3K4
trimethylation, arresting the mechanism of trained immunity
induced in vitro by BCG. Single nucleotide polymorphisms
associated with bladder cancer progression and recurrence, in
the autophagy genes ATG2B (rs3759601) and ATG5 (rs2245214),
affected both the in vitro and in vivo training effect of BCG (150).
Muramyl dipeptide (MDP), a synthetic peptide of N-acetyl
muramic acid attached to a short amino acid chain of L-Ala-
D-isoGln, is a bacterial cell wall peptidoglycan active as NOD2
agonist and contributing to the generation of trained monocytes
(151). Interestingly, Paclitaxel conjugated to MDP showed not
only antitumor activity, but also immune enhancement capacity.
In fact, compared with either paclitaxel or MDP alone, the
combination significantly increased the expression and secretion
of TNFα and IL-12 from mouse peritoneal monocytes (152).
Moreover, it was shown that MDP can upregulate PD-L1 in
healthy monocytes, but in patients with Crohn’s disease, carrying
the Leu1007 frameshift mutation of the NOD2 gene, such effect
was completely lost (153) (Table 2).
Targeting Signaling Pathways
An alternative approach to target trained immunity is to
inhibit the pathway Dectin-1-Akt-mTOR-HIF-1α. To this end,
the beneficial effects of Metformin and Everolimus, an mTOR
activator rapamycin analog, administration to patients with
type 2 diabetes and cancer, respectively, were linked with the
modulation of trained monocytes (67, 90, 154). Interestingly,
inhibitors of other kinases, such as Raf-1, PI3K, and ERK are
of particular interest in modulating trained monocytes because
they represent downstream effectors of Dectin-1 and NOD2
activation (Table 2). In particular the knockout of PI3Kγ was
reported to break tumor tolerance by MDSC reduction (54) as
well as, the combination targeting of PI3Kδ in association with
PD-L1- based immunotherapy better limited tumor progression
(155, 156). Moreover, the pharmacological treatment using
multi-kinase inhibitors carbozantinib and BEZ235, which limit
MDSC accumulation, in combination with immune checkpoint
therapy controlled more efficiently tumor growth in a castration-
resistant prostate tumor model than the single agents (157)
underlying the possibility to overcame de novo resistance to
antibody blockade based therapy by limiting MDSCs.
The development of epigenetic modulators is acquiring
increased interest due to the relevance of epigenetic changed
in several diseases. The broad jumonji histone demethylase
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TABLE 2 | Inhibitors and their corresponding targets found to impact pathways regulating different aspects of monocyte biology.
Effect Target Drug name Targeted monocyte
subset
References (PMID)
Recruitment abrogation CCR2 PF04136309
Carlumab
Inflammatory monocytes
M-MDSCs
27055731
22907596
CFS1R ARRY-382
FPA008
GW2580
Patrolling monocytes
M-MDSCs
29872489
20008303
16249345
IL-6R mAb 15A7 Patrolling monocytes
M-MDSCs
28235765
22653638
Attenuating RNS
generation
AT38 M-MDSCs 21930770
Multi-kinase carbozantinib BEZ235 M-MDSCs 28321130
amino-biphosphonates matrix metalloproteases M-MDSCs 12912933
Apoptosis induction FLIP 5-fluorouracil
Gemcitabine
Docetaxel
Paclitaxel
Oxaliplatin
Cisplatin
Irinotecan
Etoposide
M-MDSCs 30518925
Fas IL-2 with anti-CD40
antibody (clone
FGK115B3)
M-MDSCs 24808361
IL1R Anakinra Monocytes 29808007
Inhibition of proliferation GM-CSF mAb clone MP1-22E9 M-MDSCs 22698406
G-CSF mAb clone MAB414 M-MDSCs 19346489
VEGF mAb clone G6.23 M-MDSCs 17664940
Metabolic alteration Mevalonate-cholesterol
pathway
Statins Trained monocytes 29328908
NOD2 Muramyl dipeptide Trained monocytes
mTOR Everolimus
Metformin
Trained monocytes 25258083
27926861
23415113
Bromodomains I-BET151 Trained monocytes 27863248
Histone deacetylase JIB-04 Trained monocytes 23792809
29702467
Glutamine-pathway DON Trained monocytes 30541099
297024
Immunosuppressive function pSTAT3 Stattic M-MDSCs 23454751
COX2 Celecoxib M-MDSCs 21324923
IDO1 1-methyl-L-tryptophan
Epacadostat
M-MDSCs 23440412
ARG1 CB-1158
NCX 4016
NG-hydroxy-L-arginine
[NOHA]
Nω-hydroxy-nor-
Arginine [Nor-NOHA]
M-MDSCs 29254508
29133913
Phosphodiesterase
(PDE5)
Sildenafil, tadalafil M-MDSCs 27495172
25564570
PD-L1/CTLA-4 Atezolizumab
ipilimumab
M-MDSCs 28364000
30267200
Cell differentiation Retinoic acid receptor ATRA M-MDSCs 18006848
ENTPD2 POM-1 M-MDSCs 28894087
inhibitor JIB-04 decreased trained immunity response
by modulating of the methylation status of H3K9 (158).
Interestingly, a clinically relevant small molecule of the BET
family of bromodomains, I-BET151, was shown to prevent
monocyte tolerance when administered concomitantly with LPS,
but it was ineffective when administered after LPS stimulation.
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These results suggest that I-BET151 is not an effective treatment
in monocytes that have already experienced an inflammatory
response (159) (Table 2).
Targeting Metabolic Pathways
Metabolic modulation also represents another interesting
approach to target both trained monocytes andM-MDSCs. Some
metabolites and metabolic enzymes function as either substrates
or cofactors for chromatin modifying enzymes, thereby
influencing the epigenetic landscape of target cells. Accordingly,
fumarate can increase trained immunity by increasing H3K4me3
and H3K27ac and inhibiting the degradation of HIF-1α (90).
Moreover, the decreased expression of lysine demethylase 5
family of HDAC (KDM5), responsible for H3K4 demethylation,
is also inhibited by fumarate, maintaining then the accessibility
of the chromatin. On the other hand, it was shown that tolerant
monocytes lack the activity of KDM5, whose function can
be restored by its cofactor, α-ketoglutarate (90). Mevalonate,
intermediate of the cholesterol pathway has been shown to
induce trained immunity (74), consequently, statins can be used
to prevent this process under conditions in which accumulation
of trained monocytes is detrimental, like patient with hyper-IgD
syndrome or inflammatory conditions. Additionally, given the
enhanced glutamynolysis associated to trained immunity (90),
administration of 6-diazo-5-oxo-L-norleucine (DON), which
inhibits glutamine uptake and metabolism, was shown to have
favorable effects after organ transplant preventing rejection
(160) (Table 2). Even though targeting metabolic pathways, to
modulate trained monocyte function, is feasible, toxicity, and
side effects represent the main drawbacks of metabolic drugs.
Overcoming this limitation, for example, by delivering drugs
trough nanoparticles/nanocarriers, could open the access to a
variety of molecules that have already demonstrated their efficacy
in vitro.
Targeting Immunosuppressive Monocytes
(M-MDSC)
Together with trained monocytes, MDSCs represent the other
group of targetable cells. Proliferating T cells need a large
supply of amino acid like L-arginine and L-tryptophan. MDSCs
have developed a strategy to modulate local concentrations
of these amino acids via the up regulation of enzymes
involved in their degradation like ARG1, NOS2, and IDO.
Developing inhibitors of these enzymes represent a field of
intense research. To this end, nitroaspirin, consisting of a nitric
oxide group covalently linked to aspirin, was shown to restore
L-arginine levels in T cells, by suppressing the production of
ROS and iNOS (161). Moreover, our laboratory showed that
treatment with AT38 [3-(aminocarbonyl) furoxan-4-yl]methyl
salicylate], decreased MDSC-induced nitration within the tumor
environment, increasing CCL2 binding and T cell tumor
infiltration in mice (60). N-hydroxy-L-arginine (NOHA) is
an intermediate in the conversion of arginine to citrulline
and NO by iNOS (162) (Table 2). It is a potent physiologic
inhibitor of ARG1. Mice exposed to NOHA demonstrated
inhibition of MDSC function, and mice with B cell lymphoma
treated with NOHA had decreased numbers of circulating
Treg cells and improved immune responses to the cancer
(163). We also demonstrated that the production of polyamine
by ARG1 activity promotes IDO1 activation through Src
kinase signaling (164). Therefore, a combined targeting of
ARG1 and IDO1 using pharmacological compounds (165)
could be an effective treatment to constrain tumor-associated
immunosuppression improving cancer immunotherapy. MDSCs
generate an immunosuppressive environment also by producing
prostaglandin E2 (PGE2), which levels are regulated through the
enzyme Cox2 (166). PGE2 activates PGE2-R on MDSCs altering
the differentiation of MDSCs. In the bone marrow, activation of
PGE2-R hampers the differentiation of monocytes into antigen
presenting cells, while increased PGE2 switch monocytes into
MDSCs via increased expression of IDO, IL-4Rα, iNOS, and
IL-10 (167, 168). In line with these findings, blocking the
production of PGE2 in mice bearing lung carcinoma, with Cox2
inhibitors, decreased the expression of ARG1 in MDSC and
tumor growth (169). Cox2 inhibitors may also provide other
antitumor effects (Table 2). Celecoxib, a Cox2 inhibitors, was
shown to decreaseMDSC recruitment and increased CD8+ T cell
tumor infiltration in gliomas and colon carcinoma by decreasing
CCL2 production (170).
Methionine, an essential amino acid for normal T cells
function, is generally supplied by antigen presenting cells. DCs
and macrophages import cysteine to create methionine, which
is then secreted; they additionally release thioredoxin converting
cysteine to methionine. However, in the TME, MDSCs transport
cysteine intracellularly thus depleting T cells of methionine
(171, 172). Consequently, blocking thioredoxin could prevent
T cells proliferation arrest. In this situation small molecules or
neutralizing antibodies targeting extracellularly released enzymes
could be beneficial to restore T cells function and used in
combination with ACT of tumor specific T cells or with check
point inhibitors.
Constitutive activation of the JAK-STAT pathway has been
implicated in the proliferation of MDSCs via anti-apoptotic
and pro-proliferative genes (173). Moreover, ARG1 and iNOS,
immunosuppressive enzymes in MDSCs, are controlled via
STAT1 and STAT3 (174). Consequently, inhibition of the JAK-
STAT pathway has been of great interest. Many inhibitors of
STAT1/STAT3 have been discovered and several of them already
enter clinical trials. Among those one, Stattic, an inhibitor of
pSTAT3, reduces the suppressive activity of MDSC in vitro both
in mice and in humans (175, 176) (Table 2).
In the last 10 years, several approaches to target
immunosuppressive monocyte referred as M-MDSC were
developed using a large spectrum of pharmacological compounds
and immunotherapeutic approaches with the aim to limit
MDSC proliferation, function, and recruitment to tumor
site. For instance, non-therapeutic low doses of conventional
chemotherapeutic drugs such as gemcitabine and 5-fluorouracil
[which does not induce immunogenic cancer-cell death of
tumor cells (177)] were able to limit Ly6C+MDSC number and
activity by inducing c-FLIP down-regulation (65). The M-MDSC
elimination is essential to restore the immune response in
tumor-bearing mice by rescuing the frequency of circulating
anti-tumor T cells (51). These data obtained in preclinical cancer
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models were also confirmed in tumor patients. In fact, renal
cell cancer (RCC) patients with low frequency of M-MDSCs
showed a better disease control after anti-tumor peptide-based
vaccination in combination with chemotherapy (178); moreover,
the HPV16 long-peptide-based vaccination during CarboTaxol
treatment was able to reduce circulating MDSCs and generated a
strong immune response, confirming the relevance of M-MDSC
elimination as a valid approach to enforce anti-tumor immune
response (179). Based on these data, several chemotherapeutic
compounds with different mechanisms of action were listed as
M-MDSC-targeting drugs (173). M-MDSC elimination can be
also achieved using immune compounds such cytokines and
antibodies. In this line, the combination of IL-2 with anti-CD40
antibody was effective on cancer growth control in two different
mouse tumor models by inducing M-MDSC elimination trough
Fas-mediated apoptosis (180). Similarly, to improve the efficacy
of CAR T cells immunotherapy in leukemia setting, by limiting
transferred T cells-associated life-threatening cytokine-release
syndrome (CRS) and neurotoxicity, either monocyte-depletion
or infusion of IL-1 receptor antagonist anakinra were reported
as effective strategies (181). Other therapeutic approaches
aim at favoring MDSC differentiation into anti-tumoral cell
subsets such as macrophages and DCs. For example, all-trans-
retinoic acid (ATRA) treatment was reported to promote the
differentiation of MDSC into mature anti-tumoral myeloid cells
via the activation of the ERK1/2 signaling pathway (182) as well
as the treatment with 25-hydroxyvitamin D3 was reported to
reduce the frequency of immature immune suppressive cells in
peripheral blood of HNSCC patients (183). Moreover, M-MDSC
differentiation toward mature anti-tumoral monocytes-derived
DCs can be achieved using pharmacological inhibitor of
ATP-converting ectoenzyme ENTPD2, thus mitigating cancer
growth and enhancing the efficiency of immune checkpoint
inhibitors (184). Finally, some targeting approaches aim at
blocking M-MDSC migration from bone marrow to tumor
site. For example, amino-biphosphonates were able to prevent
the activation of matrix metalloproteases (MMPs) limiting
cancer aggressiveness and distal spread (185). Along the same
line, pharmacological antagonist of chemokine receptors (i.e.,
S-265610, CXCR2-specific antagonist) were able to drastically
reduce M-MDSC in tumor-bearing mice (186).
CONCLUDING REMARKS
Monocytes are relevant immunological cells connecting the
innate and adaptive immune compartments. Here, we have
attempted to integrate recent advances in the molecular,
metabolic, and functional aspects of monocyte biology with the
current state of understanding about the role of these cells in
cancer growth and metastatic spread. Although a large body of
evidence supports the notion that circulating monocytes serve
only as precursor cells that replenish tissue macrophages and DC
populations, the overwhelming complexity underlined by high
throughput technologies, is supporting a direct contribution of
monocyte to cancer development. Targeting monocytes at the
immunological, metabolic, epigenetic, and transcriptional level is
a promising strategy to treat both disease with impaired immune
function, like cancer, or with over-reactive immune response,
like autoimmune diseases. The advances in our knowledge
on monocyte development, response, and reprogramming,
particularly during cancer evolution and metastatic spread, will
pave the way for the development of new therapeutic strategy
with specificity and limited toxicity.
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